UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Lazar David E.				2. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTNP]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner				
(Last) (First) (Middle) VILLA 1, 14-43RD STREET, JUMEIRAH 2				3. Date of Earliest Transaction (Month/Day/Year) 07/06/2022											below)	
(Street) DUBAI, C0 00000												6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_Form filed by More than One Reporting Person				
(Zip)			Т	able I -	Non	-D	erivative S	ecurit	ies Acau	ired T	Disno	sed of or I	Reneficially	Owned		
2. Transaction Date (Month/Day/Year)	Execution any	A. Deemed Execution Date, if		3. Transaction Code			4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)) 5. Amount of Securities			6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	V	,	Amount	or						(I) (Instr. 4)	(msu. 4)	
07/06/2022				P			1,165,975	5 A	\$ 0.773 (3)	5 2,5	87,1	.08		D (1) (2)		
07/07/2022				P			744,294	A	\$ 0.992 (4)	9 3,3	31,4	102		D (1) (2)		
07/06/2022				P			315,921	A	\$ 0.892 (6)	6 359	359,066			I	By Activist Investing LLC (1) (2) (5)	
e for each class of se	curities l	beneficial	lly o	wned d	I	Pe	rsons who	resp	form are	e not i	equ	ired to res	spond unl	ess	C 1474 (9-02	
Table I											ned					
exercise Date Execution Date (Month/Day/Year) Execution Date		4. 5. Number Code of Deriva Securit (A) or Dispos of (D) (Instr. 8)		er ative ties red sed 3,	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. T Am Und Sec	. Title and mount of Inderlying ecurities Instr. 3 and		Derivative Security	Derivative Securities Beneficially Owned Following Reported	Owners Form o Derivat Securit Direct (or India	f Beneficia Ownersh (y: (Instr. 4)			
								Expirat	tion Title	Amo or Num of						
	(Middle) T, JUMEIRAH 2 (Zip) 2. Transaction Date (Month/Day/Year) 07/06/2022 07/07/2022 e for each class of se Table II ction ay/Year) 3A. Deeme Execution any	TIT 3. D 07/06/2022	(Middle) T, JUMEIRAH 2 3. Date of Ea	TITAN PHAF (Middle) T, JUMEIRAH 2 3. Date of Earlies 07/06/2022 4. If Amendment 2. Transaction Date (Month/Day/Year) 07/06/2022 07/06/2022 e for each class of securities beneficially of the company of the comp	TITAN PHARMAC (Middle) T, JUMEIRAH 2 3. Date of Earliest Trans 07/06/2022 4. If Amendment, Date C Execution Date, if any (Month/Day/Year) 2. Transaction Date (Instr. 8) Code (Instr. 8) 7. Transaction Code (Instr. 8) 8. Numb of Derivative Securities Acc (e.g., puts, calls, warrants (A) or Dispos of (D) (Instr. 8)	TITAN PHARMACEUT (Middle) T, JUMEIRAH 2 3. Date of Earliest Transaction 07/06/2022 4. If Amendment, Date Origin (Zip) Table I - Non 2. Transaction Date (Month/Day/Year) (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) P 07/06/2022 P 07/06/2022 P 07/06/2022 P 07/06/2022 P Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, opton any (Month/Day/Year) Table II - Derivative Securities Acquire (e.g., puts, calls, warrants, opton any (Month/Day/Year) (Month/Day/Year) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) [Instr. 3, 4, and 5)	TITAN PHARMACEUTI 3. Date of Earliest Transaction (07/06/2022 4. If Amendment, Date Original 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 07/06/2022 P 07/06/2022 P 07/06/2022 P 07/06/2022 P 07/06/2022 P Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optio any (Month/Day/Year) Execution Date, if any (e.g., puts, calls, warrants, optio of any (Month/Day/Year) Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optio of any (Month/Day/Year) (Instr. 8) Table II - Derivative Securities Acquired, (e.g., puts, calls, warrants, optio of (D) (Instr. 3, 4, and 5)	TITAN PHARMACEUTICALS IN 3. Date of Earliest Transaction (Month/Day/07/06/2022 4. If Amendment, Date Original Filed(Month/Day/1998) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction Date, if (Month/Day/Year) 2. Transaction Date, if (Instr. 8) Code V Amount 4. Securities or Disposed (Instr. 3, 4: (Instr. 8)) 7. Table II - Derivative Securities Acquired, Disposed of (D) (Instr. 8) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4; and 5) Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4; and 5)	TITAN PHARMACEUTICALS INC [T] 3. Date of Earliest Transaction (Month/Day/Year) 07/06/2022 4. If Amendment, Date Original Filed(Month/Day/Year) 2. Transaction Date (Month/Day/Year) 2. Transaction (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) 4. Securities Acquired, (Instr. 8) 4. O7/06/2022 P 1,165,975 A Presons who respective in the form displays Table II - Derivative Securities Acquired, Disposed of, or B (e.g., puts, calls, warrants, options, convertible securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (A) or Disposed of (D) (Instr. 3, 4, and 5)	TITAN PHARMACEUTICALS INC [TTNP] 3. Date of Earliest Transaction (Month/Day/Year) (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3) A mount (D) Price (Zip) Table I - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 8) (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 8) (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 8) (Instr. 8) 7. Jument (A) or Disposed of (D) (Instr. 8) 7. Jument (D) Price 1. Jument (D) Price 1. Jument (D) Price 8. Jument (D) Price 1. Jument (D) Price 8. Jument (D) Price 1. Jument (D) Price 2. Transaction (D) Price 3. Jument (D) Price 4. Jument (D) Price 2. Transaction (D) Price 2. Transaction (D) Price 3. Jument (D) Price 4. Jument (D) Price 2. Transaction (D) Price 3. Jument (D) Price 3. Jument (D) Price 4. Jument (D) Price	TITAN PHARMACEUTICALS INC [TTNP] (Middle) 3. Date of Earliest Transaction (Month/Day/Year) (707/06/2022 4. If Amendment, Date Original Filed(Month/Day/Year) (Zip) Table I - Non-Derivative Securities Acquired, Execution Date, if (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Transaction any (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Transaction any (Month/Day/Year) (Month/Day/Year) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (A) or Disposed of (D) (Instr. 3, 4 and 5) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Instr. 3) (Month/Day/Year) (Month/Day/Year) (Instr. 3) (Month/Day/Year) (Month/Day/Year)	TITAN PHARMACEUTICALS INC [TTNP] Code	TITAN PHARMACEUTICALS INC [TTNP] Middle	TITAN PHARMACEUTICALS INC [TTNP] (Middle) T, JUMEIRAH 2 O7/06/2022 4. If Amendment, Date Original Filed(Month/Day/Year) O7/06/2022 4. If Amendment, Date Original Filed(Month/Day/Year) Table 1 - Non-Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) O7/06/2022 P 1,165,975 A 0,7735 2,587,108 (3) O7/07/2022 P 315,921 A 0,8926 359,066 (6) Table I - Derivative Securities Acquired (A) or or Disposed of (D) (Instr. 3) (A) (Instr. 4) (A) (Instr. 5) (A) (Instr. 6) (A) (Instr	TITAN PHARMACEUTICALS INC [TTNP] (Middle) 3. Date of Earliest Transaction (Month/Day/Year) T, JUMEIRAH 2 (Zip) Table 1 - Non-Derivative Securities Acquired (A) Date (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Month/Day/Year) (Zip) Table 1 - Non-Derivative Securities Acquired (A) Date (Month/Day/Year) (Month/Day/Year)	

	Relationships				
	Director	10% Owner	Officer	Other	
Reporting Owner Name / Address					

Lazar David E. VILLA 1, 14-43RD STREET JUMEIRAH 2 DUBAI, C0 00000	X	
Activist Investing LLC 1185 AVENUE OF THE AMERICAS, 3RD FLOOR. NEW YORK, NY 10036		Member of 10% owner group

Signatures

/s/ David E. Lazar	07/08/2022
**Signature of Reporting Person	Date
Activist Investing LLC, By: /s/ David E. Lazar, Chief Executive Officer	07/08/2022
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This Form 4 is filed jointly by Activist Investing LLC ("Activist Investing") and David E. Lazar (collectively, the "Reporting Persons").
- (2) Each Reporting Person disclaims beneficial ownership of the securities of the Issuer reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such securities for purposes of Section 16 or any other purpose.
- Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from \$0.5982 to \$0.9964. The Reporting Persons undertake to (3) provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
- Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from \$0.8399 to \$1.1000. The Reporting Persons undertake to (4) provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
- (5) Securities of the Issuer beneficially owned directly by Activist Investing. Mr. Lazar, as the sole member and Chief Executive Officer of Activist Investing, may be deemed the beneficial owner of the securities of the Issuer beneficially owned by Activist Investing.
- Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from \$0.6640 to \$0.9499. The Reporting Persons undertake to (6) provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.